Many people are at the very least iffy about the idea of extending human healthy lifespan through medical biotechnologies that prevent age-related diseases essentially by rejuvenating the body. Even people who accept the possibility that such therapies can be developed are not convinced that developing them is a good idea, and there are only a few arguments that most people use. These arguments can actually be easily adapted to make a case against the medicine that already exists, which the vast majority of people on the planet currently benefit from—and the consensus is virtually universal that people who do not yet benefit from it should be given this opportunity as soon as possible.

The question is: would people who accept these arguments as valid objections to rejuvenation accept them also as valid objections against “normal” medicine? For example, how many present-day people would agree with what these two people from the 1600s are talking about?

A – Did you hear about John’s son?

Just as plastic tips protect the ends of shoelaces and keep them from fraying when we tie them, molecular tips called telomeres protect the ends of chromosomes and keep them from fusing when cells continually divide and duplicate their DNA. But while losing the plastic tips may lead to messy laces, telomere loss may lead to cancer.

Salk Institute scientists studying the relationship of telomeres to cancer made a surprising discovery: a cellular recycling process called autophagy—generally thought of as a survival mechanism—actually promotes the death of cells, thereby preventing cancer initiation.

The work, which appeared in the journal Nature on January 23, 2019, reveals autophagy to be a completely novel tumor-suppressing pathway and suggests that treatments to block the process in an effort to curb cancer may unintentionally promote it very early on.

With the dramatic demonetization of genome reading and editing over the past decade, and Big Pharma, startups, and the FDA starting to face aging as a disease, we are starting to turn those answers into practical ways to extend our healthspan.

Here, in Part 2 of a series of blogs on Longevity & Vitality, I explore how genome sequencing and editing, along with new classes of anti-aging drugs, are augmenting our biology to further extend our healthy lives.

In this blog I’ll cover two classes of emerging technologies:

Over the past 100 hundred years, the average human lifespan has increased dramatically, thanks to exponential advancements in science and technology. While living to 80, 90, and even 100 is a possibility, humans have long been in search of the ultimate discovery – immortality.

In order to achieve immortality, scientists have identified four key issues that must be overcome. These include telomere shortening, chronological aging, oxidative stress, and glycation. If these could be drastically reduced or even eliminated, immortality may just be in our reach. However, there are some promising technologies that are prolonging the human lifespan right now, and could eventually lead us to immortality.

It is definitely a creepy a concept to think about, but studies have shown that regular blood transfusions sourced can extend the human lifespan by 10–20 years. Scientists have found that a protein called GDF11 is very common in the blood of young mice, and has been shown to increase skeletal muscle and increase heart strength. This protein has been deemed to have anti-aging properties, making it a promising technology in extending human lifespan.